Virologic, clinical, and immunological characteristics of a dengue virus 3 human challenge model
Waickman, A. T.; Newell, K.; Lu, J. Q.; Fang, H.; Waldran, M.; Gebo, C.; Currier, J. R.; Friberg, H.; Jarman, R. G.; Klick, M. D.; Ware, L. A.; Endy, T. P.; Thomas, S. J.
Show abstract
Dengue human infection models present an opportunity to explore a vaccine, antiviral, or immuno-compounds potential for clinical benefit in a controlled setting. Herein, we report the outcome of a phase 1, open-label assessment of a DENV-3 challenge model. In this study, 9 participants received a subcutaneous inoculation with 0.5ml of a 1.4x103 PFU/ml suspension of the DENV-3 strain CH53489. All subjects developed RNAemia within 7 days of inoculation, with peak titers ranging from 3.13x104 to 7.02x108 GE/ml. Symptoms and clinical lab abnormalities consistent with mild dengue infection were observed in all subjects. DENV-3 specific seroconversion was observed by 14 days after inoculation, along with DENV-3 specific memory T cell responses. RNAseq and serum cytokine analysis revealed the presence of an antiviral transcriptional and cytokine response to infection that overlapped with the period of viremia. The magnitude and frequency of clinical and immunologic endpoints correlated with an individuals peak viral titer.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Frequency of Dengue Virus-Specific T Cells is related to Infection Outcome in Endemic Settings 95%
- Asymptomatic or mild symptomatic SARS-CoV-2 infection elicits durable neutralizing antibody responses in children and adolescents 95%
- Vaccine Breakthrough Infection with the SARS-CoV-2 Delta or Omicron (BA.1) Variant Leads to Distinct Profiles of Neutralizing Antibody Responses 95%
Similar papers in this journal
- Elite neutralizers of human cytomegalovirus are characterized by high magnitude plasma IgG responses against multiple glycoprotein complexes 95%
- SARS-CoV-2 evolution and patient immunological history shape the breadth and potency of antibody-mediated immunity 95%
- A bivalent Adenovirus-Vectored Vaccine induces a measurable humoral response, but does not protect cynomolgus macaques against a lethal challenge with Sudan virus 94%
Similar papers in this journal
- Temporally integrated single cell RNA sequencing analysis of controlled and natural primary human DENV-1 infections 98%
- Pre-vaccination Frequency of Circulatory Tfh is associated with Robust Immune Response to TV003 Dengue Vaccine 95%
- DENV-specific IgA contributes protective and non-pathologic function during antibody-dependent enhancement of DENV infection 95%
Similar papers in this journal
- Evolution of inflammation and immunity in a dengue virus 1 human infection model 99%
- Immune Responses in Fully Vaccinated Individuals Following Breakthrough Infection with the SARS-CoV-2 Delta Variant in Provincetown, Massachusetts 94%
- Loss of recognition of SARS-CoV-2 B.1.351 variant spike epitopes but overall preservation of T cell immunity 94%
Similar papers in this journal
- Isolation of a potently neutralizing and protective human monoclonal antibody targeting yellow fever virus 96%
- Low levels of H5N1 HA and NA antibodies in the human population are boosted by seasonal A/H1N1 infection but not by A/H3N2 infection or influenza vaccination 94%
- SARS-CoV-2 infection severity is linked to superior humoral immunity against the spike 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.